Treatment of adult systemic mastocytosis with interferon-α: Results of a multicentre phase II trial on 20 patients

British Journal of Haematology

Volumn 119, Issue 4, 2002, Pages 1090-1097

  Casassus, Philippe ^a   Caillat Vigneron, Nadine ^b   Martin, Antoine ^a   Simon, Jeanne ^c   Gallais, Valérie ^a   Beaudry, Patrice ^d   Eclache, Virginie ^e   Laroche, Liliane ^a   Lortholary, Pierre ^f   Raphaël, Martine ^f   Guillevin, Loïc ^a   Lortholary, Olivier ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b Service de Medecine Nucleaire   (France)

^c Hôpital Cochin ^*  (France)

^d HÔPITAL LARIBOISIÈRE   (France)

^e HÔPITAL JEAN VERDIER   (France)

^f Service d Hématologie Biologique   (France)

Author keywords

Interferon ; Mediators; Systemic mastocytosis; Vascular congestion

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON; STEROID;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DEPRESSION; DOSE RESPONSE; FEMALE; HEART INFARCTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPHOCYTIC INFILTRATION; MALE; MAST CELL; MEDIATOR RELEASE; MULTICENTER STUDY; PALLIATIVE THERAPY; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; REMISSION; SEPTIC SHOCK; SKIN DEFECT; STEROID THERAPY; SYSTEMIC MASTOCYTOSIS; TREATMENT OUTCOME;

ADULT; AGED; BONE MARROW; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HISTAMINE; HUMANS; IMIDAZOLES; INTERFERON ALFA-2B; MALE; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; PROSPECTIVE STUDIES; SERINE ENDOPEPTIDASES; TREATMENT OUTCOME; TRYPTASES;

EID: 0036454699     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03944.x     Document Type: Article

References (38)

1. Caillat-Vigneron, N., Lortholary, O., Guillevin, L., Raphaël, M. & Casassus, P. (1994) Staging of systemic mastocytosis: Bone marrow scintigraphy, cytology and bone scan, a preliminary study. Blood, 84, 2504.
2. Czarnetzki, B.M., Algermissen, B., Jeep, S., Haas, N., Nürnberg, W., Müller, K. & Kropp, J.D. (1994) Interferon treatment of patients with chronic urticaria and mastocytosis. Journal of the American Academy of Dermatology, 30, 500-501.
3. Delaporte, E., Piérard, E., Wolthers, B.G., Desremaux, P., Janin, A., Cortot, A., Piette, F. & Bergoend, H. (1995) Interferon-α in combination with corticosteroids improves systemic mast cell disease. British Journal of Dermatology, 132, 479-482.
4. Fain, O., Sitbon, M., Sibony, M., Frilay, Y., Mathieu, E., Lejeune, F. & Thomas, M. (1995) Efficacité de l'interféron alpha dans un cas de mastocytose systémique. Annales de Médecine Interne (Paris), 146, 205-206.
5. Golkar, L. & Bernhard, J.D. (1997) Mastocytosis. Lancet, 349, 1379-1385.
6. Granerus, G. & Wass, U. (1984) Urinary excretion of histamine, methylhistamine and methylimidazoleacetic acid in mastocytosis: Comparison of new HPLC methods with other present methods. Agents Actions, 14, 341-345.
7. Guilhot, F., Chastang, C., Michallet, M., Guerci, A., Harousseau, J.L., Maloisel, F., Bouabdallah, R., Guyotat, D., Cheron, N., Nicolini, F., Abgrall, J.F. & Tanzer, J. for the French Chronic Myeloid Leukemia Study Group (1997) Interferon alpha-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. New England Journal of Medicine, 337, 223-229.
8. Haimart, M., Launay, J.M., Zürcher, G., Cauet, N., Dreux, C. & Da Prada, M. (1985) Simultaneous determination of histamine and N-methylhistamine in biological samples by an improved enzymatic single isotope assay. Agents Actions, 16, 71-75.
9. He, S., Gaça, M.D.A. & Walls, S.A. (1998) A role for tryptase in the activation of human mast cells: Modulation of histamine release by tryptase and inhibitors of tryptase. The Journal of Pharmacology and Experimental Therapeutics, 286, 289-297.
10. Horny, H.P., Ruck, P., Krober, S.M. & Kaiserling, E. (1997) Systemic mast cell disease (mastocytosis). General aspects and histopathological diagnosis. Histology and Histopathology, 12, 1081-1089.
11. ISCN (1995) Guidelines for Cancer Cytogenetics: Supplement to an International System for Human Cytogenetic Nomenclature (ed. by F. Mitelman). Karger, Basel.
12. Kluin-Nelemans, H.C., Jansen, J.H., Breukelman, H., Wolthers, B.G., Kluin, P.M., Kroon, M.D. & Willemze, R. (1992) Response to interferon alpha-2b in a patient with systemic mastocytosis. New England Journal of Medicine, 326, 619-623.
13. Kolde, G., Sunderkötter, C. & Luger, T.A. (1995) Treatment of urticaria pigmentosa using interferon alpha. British Journal of Dermatology, 133, 91-94.
14. Kraus, M.R., Schafer, A. & Scheurlen, M. (2001) Paroxetine for the prevention of depression induced by interferon alpha. New England Journal of Medicine, 345, 375-376.
15. Krober, S.M., Horny, H.P., Ruck, P., Kammerer, U., Geiselhart, A., Handgretinger, R., Grieser, H., Menke, D.M. & Kaiserling, E. (1997) Mastocytosis: Reactive or neoplastic? Journal of Clinical Pathology, 50, 525-527.
16. Lehmann, T., Beyeler, C., Lämmle, B., Hunziker, T., Vock, P., Olah, A.J., Dahinden, C. & Gerber, N.J. (1996) Severe osteoporosis due to systemic mast cell disease: Successful treatment with interferon alpha-2b. British Journal of Rheumatology, 35, 898-900.
17. Lippert, U. & Henz, B.M. (1996) Long-term effect of interferon alpha treatment in mastocytosis. British Journal of Dermatology, 134, 1164-1165.
18. Longley, B.J., Tyrrell, L., Lu, S.Z., Ma, Y.S., Langley, K., Ding, T.G., Duffy, T., Jacobs, P., Tang, L.H. & Modlin, I. (1996) Somatic c-KIT-activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm. Nature Genetics, 12, 312-314.
19. Longley, J., Duffy, T.P. & Kohn, S. (1995) The mast cell and mast cell disease. Journal of the American Academy of Dermatology, 32, 545-561.
20. Lortholary, O., Casassus, P., Laroche, L., Lortholary, P. & Diebold, J. (1990) Mastocytoses systémiques et mastocytoses malignes. Presse Médicale, 19, 125-128.
21. Lortholary, O., Audouin, J., Le Tourneau, A. & Diebold, J. (1991a) Le mastocyte et sa pathologie. Nosologie et physiopathologie des hyperplasies et proliférations mastocytaires. Annales de Pathologie, 11, 18-24
22. Lortholary, O., Audouin, J., Le Tourneau, A. & Diebold, J. (1991b) Le mastocyte et sa pathologie. Histopathologie des mastocytoses. Annales de Pathologie, 11, 92-100.
23. Metcalfe, D.D. (1991a) Classification and diagnosis of mastocytosis: Current status. The Journal of Investigative Dermatology, 96, s2-s4.
24. Metcalfe, D.D. (1991b) The treatment of mastocytosis: An overview. The Journal of Investigative Dermatology, 96, s55-s59.
25. Nagata, H., Worobec, A.S., Oh, C.K., Chowdhury, B.A., Tannenbaum, S., Suzuki, Y. & Metcalfe, D.D. (1995) Identification of a point mutation in the catalytic domain of the protooncogene c-KIT in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proceedings of the National Academy of Sciences of the United States of America, 92, 10560-10564.
26. Parawaresch, M.R., Horny, H.P. & Lennert, K. (1985) Tissue mast cells in health and disease. Pathology, Research and Practice, 179, 439-461.
27. Pardini, S., Bosincu, L., Bonfigli, S., Dore, F. & Longinotti, M. (1991) Anaphylactic-like syndrome in systemic mastocytosis treated with alpha-2 interferon. Acta Haematologica, 85, 220.
28. Petit, A., Pulik, M., Gaulier, A., Lionnet, F., Mahe, A. & Sigal, M. (1995) Systemic mastocytosis associated with chronic myelo-monocytic leukemia: Clinical features and response to interferon alpha therapy. Journal of the American Academy of Dermatology, 32, 850-853.
29. Pignon, J.M. (1997) C-kit mutations and mast cell disorders. A model of activating mutations of growth factor receptors. Hematology and Cell Therapy, 39, 114-116.
30. Pignon, J.M., Giraudier, S., Duquesnoy, P., Jouault, H., Imbert, M., Vainchenker, W., Vernant, J.P. & Tulliez, M. (1997) A new c-KIT mutation in a case of aggressive mast cell disease. British Journal of Haematology, 96, 374-376.
31. Poynard, T., Bedossa, P., Chevallier, M., Mathurin, P., Lemonnier, C., Trepo, C., Couzigou, P., Payen, J.L., Sajus, M. & Costa, J.M. (1995) A comparison of three interferon alpha-2b regimens for the long term treatment of chronic non-A, non-B hepatitis. New England Journal of Medicine, 332, 1457-1462. (Erratum, New England Journal of Medicine (1996), 334, 1143.)
32. Schwartz, L.B. (1994) Tryptase: A mast cell serine protease. Methods in Enzymology, 244, 88-100.
33. Swieter, M., Ghali, W.A., Rimmer, C. & Befus, D. (1989) Interferon alpha/beta inhibits IgE-dependent histamine release from rat mast cells. Immunology, 66, 606-610.
34. Travis, W.D., Li, C.Y.L., Bergstralh, E.J., Yam, L.T. & Swee, R.G. (1988) Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore), 67, 345-368.
35. Valent, P. (1996) Biology, classification and treatment of human mastocytosis. Wiener Klinische Wochenschrift, 108, 385-397.
36. Valent, P., Hornyb, H.-P., Escribanoc, L., Longley, B.J., Lie, C.Y., Schwartz, L.B., Maroneg, G., Nunez, R., Akinh, C., Sotlari, K., Sperra, W.R., Woll, K., Brunning, R.D., Parwaresch, R.M., Austen, K.F., Lennert, K., Metcalfe, D.D., Vardimann, J.W. & Bennetto, J.M. (2001) Diagnostic criteria and classification of mastocytosis: A consensus proposal. Leukemia Research, 25, 603-625.
37. Weide, R., Ehlenz, K., Lorenz, W., Walthers, E., Klausmann, M. & Pfluger, K.H. (1996) Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Annals of Hematology, 72, 41-43.
38. Worobec, A.S., Kirshenbaum, A.S., Schwartz, L.B. & Metcalfe, D.D. (1996) Treatment of three patients with systemic mastocytosis with interferon alpha-2b. Leukemia and Lymphoma, 22, 501-508.